Immunex Novantrone MS Use Is Likely To Be Second-Line
Immunex expects Novantrone (mitoxantrone) would be used primarily as second-line therapy if approved for the treatment of multiple sclerosis.
You may also be interested in...
"Novantrone is indicated for the treatment of patients with secondary progressive multiple sclerosis, including progressive relapsing disease. Novantrone has been shown to slow the progression of physical disability and neurologic impairment, reduce the frequency of clinical relapse, increase the time to the first treated relapse, and reduce the number of hospitalizations.
Schering AG expects its U.S. business to approach $1.6 bil. in revenues by 2005, more than double its projected 1999 level of $750 mil.
The next step in Wyeth-Ayerst's plans to expand the market for Enbrel will be the presentation of the pivotal trial data in early rheumatoid arthritis during the upcoming American College of Rheumatology conference in Boston, Nov. 13-17.